Longevity biotechnology – the science of extending healthy human lifespan through therapeutic intervention – is transitioning from academic research to clinical development and early commercial application. Senolytic drug developers, NAD+ therapy companies, telomere technology businesses, and longevity biomarker testing companies are all making market entry and capital raising decisions as the field achieves its first clinical milestones. GreyRadius helps longevity biotech businesses validate clinical and consumer demand, navigate regulatory pathways, execute GTM plans, and raise capital grounded in primary research with longevity clinicians, investors, and consumer health leaders.
Why now? The first longevity biotech companies are approaching clinical milestones – Unity Biotechnology, Calico, and multiple clinical-stage longevity companies are generating data that is establishing the field's commercial credibility. Gulf sovereign wealth funds, Singapore biomedical investment programmes, and private longevity investors are all actively deploying capital into longevity biotech. The fundraising and commercial positioning decisions being made in 2025–2028 will define the longevity biotech commercial ecosystem.
Global longevity biotech investment exceeded $5B in 2023 and is growing at 40%+ annually – driven by billionaire longevity investors, sovereign wealth fund health programmes, and recognition that ageing is the root cause of most chronic diseases.
Senolytics – drugs that clear senescent cells – are advancing through clinical trials for multiple age-related conditions and represent the most clinically advanced longevity therapeutic category.
Longevity biomarker testing is creating a commercial bridge between consumer health and clinical therapeutics – companies offering biological age testing and health optimisation programmes are generating revenue while clinical therapeutics develop.
The Gulf is emerging as a significant longevity biotech investment destination – Saudi Arabia's Hevolution Foundation is the world's largest dedicated longevity research funder, creating unique partnership and funding opportunities.
If you recognise your situation below, we can help.
Clinical and consumer demand validation
You need to validate longevity clinician and consumer interest in your therapeutic or diagnostic product and what evidence standards and pricing they require.
Regulatory strategy and indication selection
You need to identify the optimal regulatory pathway for your longevity therapeutic – which indication to develop, which regulatory agency to lead with, and what clinical evidence is required.
Longevity clinic and clinical partner identification
You need to identify longevity clinics, executive health programmes, and research hospitals as clinical validation and commercial distribution partners.
Raising capital for a longevity biotech company
You are raising investment and need a pitch book that clearly explains the science, clinical strategy, and commercial opportunity.
Gulf and sovereign fund investment strategy
You need to identify and engage Gulf sovereign wealth funds, national health investment programmes, and longevity-focused investors.
Consumer health channel strategy
You need a commercial strategy for reaching longevity-interested consumers through direct-to-consumer, physician-prescribing, and corporate wellness channels.
Every engagement is grounded in primary research and delivers a measurable outcome.
Validate clinical and consumer demand for longevity biotech products in a new market. Covers longevity physician and consumer surveys, regulatory pathway mapping, investor landscape assessment, and a Go/Defer/Kill recommendation.
Learn more →Full financial and operational feasibility for longevity biotech investments. Covers clinical development cost modelling, commercial market sizing, revenue model, and investor-ready financial projections.
Learn more →End-to-end market entry for longevity biotech companies. Regulatory strategy, clinical partner identification, longevity clinic distribution development, and first-clinical-programme or first-consumer milestone.
Learn more →Embedded GTM team for longevity biotech platforms. Longevity physician outreach, consumer health channel development, and first-revenue milestone tracking.
Learn more →Investor-ready pitch books for longevity biotech ventures. Clinical-milestone-validated market sizing, science narrative, and investor identification across longevity-focused VC and sovereign funds.
Learn more →AI use-case prioritisation in longevity biotech – from biomarker pattern recognition and biological age prediction to clinical trial design optimisation and personalised intervention recommendation.
Learn more →80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Healthcare · Market Entry
Healthcare · GTM Execution
Healthcare · Assessment
All three. We work with therapeutic companies on regulatory strategy and fundraising, diagnostics companies on market entry and GTM, and consumer longevity health companies on market entry and fundraising.
Gulf, Southeast Asia, and Europe – markets with active longevity investment programmes and growing premium health consumer segments.
Typically 8–12 weeks for clinical demand research, regulatory pathway mapping, and investor landscape assessment.
Yes. Gulf health investment programme mapping and investor identification are part of our fundraising advisory for longevity companies.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, Europe.
